1614 #17
9127103
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Finer et al.

Attorney Docket No.: CYTOP009C

Application No.: 09/724,778

Examiner: UNASSIGNED

Filed: November 28, 2000

Group: UNASSIGNED

Title: METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail to: Commissioner for Patents, Washington, DC 20231 on October 8, 2001.

Signed: Laura M. Dean

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.56 AND 1.97(c)

Commissioner for Patents
Washington, DC 20231

Dear Sir:

The references listed in the attached PTO Form 1449 may be material to examination of the above-identified patent application. Applicants submit the list of these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56 and 1.97. The Examiner is requested to make these references of official record in this application. The above-identified application is a continuation of prior application U.S. Patent Application No. 09/699,047. This prior application is being relied upon for an earlier filing date under 35 U.S.C. § 120. Because the listed references were either cited by the PTO, or submitted to the PTO in the prior application, under 37 CFR § 1.98(d) Applicants submit that copies need not be provided.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

This Information Disclosure Statement is: (i) filed within three (3) months of the filing date of the above-referenced application, (ii) believed to be filed before the mailing date of a first Office Action on the merits, or (iii) believed to be filed before the mailing of a first Office Action after the filing of a Request for Continued Examination under §1.114. Accordingly, it is believed that no fees are due in connection with the filing of this Information Disclosure

Statement. However, if it is determined that any fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500388 (Order No. CYTOP009C1).

Respectfully submitted,
BEYER WEAVER & THOMAS, LLP

Lauren L. Stevens
Registration No. 36,691

P.O. Box 778
Berkeley, CA 94704-0778
(650)961-8300

Form 1449 (Modified)	Atty Docket No.	Application No.:
Information Disclosure Statement By Applicant	CYTOP009C1	09/724,778
	Applicant: Finer et al.	
	Filing Date	Group
(Use Several Sheets if Necessary)	11/28/00	Unknown

U.S. Patent Documents

Examiner Initial	No.	Patent No.	Date	Patentee	Class	Sub-class	Filing Date
	A	5,783,577	21 Jul 98	Houghten et al.	514	247	13 Sept 96

Foreign Patent or Published Foreign Patent Application

Examiner Initial	No.	Document No.	Publication Date	Country or Patent Office	Class	Sub-class	Translation Yes	Translation No
	B	EP-900S68 A2	10 Mar 99	EPO	A61K 31	505		N/A
	C	DE 3721855A1	22 Sept 88	Germany	C07K5	02		X
	D	WO 9710221	20 Mar 97	PCT	C07D239	88		N/A
	E	GB 2271111A	6 April 94	GB	C07D239	90		N/A
	F	EP-0056637A1	28 Jul 82	EPO	C07D239	91		N/A

Other Documents

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	G	CHEMCATS COPYRIGHT 2000 ACS, 1998:596123 CHEMCATS, Maybridge, 3 Apr 2000, DP 01489, N2-(3-pyriaylme~hyl)-4-oxo-3,4- dihydroquinazoline-2-c~rboxamide, 190437-46-8, CHEMICAL LIBRARY.
	H	Q Kozhevnikov, V. and Pilat, N.V. [4-Ouinazolinones. II. 2-(Aminomethyl)-2-aryl-4-quinazolinones.] (Russian) **Tr Perm Sel-Khoz Inst** (79):66-72, 1971 CA 78:16128.
	I	Gupta, C.M. et al. Drugs acting on the central nervous system. Synthesis of substituted quinazolones and quinazolines and triazepino- and triazocinoquinazolones. **J Med Chem** 11 :392.395, 1968.
	J	Saari. W .S. et al. Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 2. Analogues of 2-aminopyrjdin-2(' H)-one. **J Med Chem** 35:3792.3802.1992.
	K	Farghaly, A.M. et al. Non-steroidal antiinflammatory agents. Ill: Synthesis of pyrazole derivatives of 4(3H)-quinazolinones. **Alexandria J Pharm Sci** 4(1):52.56,1990. CA 114:122242
	L	Dymek. W. et al. 2-Chloromethyl-6-methylquinazoline-4 and its transformations. **Diss Pharm et Pharmacol** 20(1):29-34, 1968.
	M	Pattanaik, J.M. et af. Synthesis and fungicidal activity of 3-aryl.2.(4'.aryl thjazol-2'-ylaminomethyl) quinazol-4(3H)-ones. **Indian J Chem** 37B:1304-1306, 1998.
	N	Gupta, D.P. and Shanker, K. Thiazolidinones. azetidinones and formazans of quinazolinones. **Indian J Chem** 26B:1197-1199. 1987.

Examiner	Date Considered

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449 (Modified)	Atty Docket No.	Application No.:
	CYTOP009C1	09/724,778
Information Disclosure Statement By Applicant	Applicant: Finer et al.	
	Filing Date	Group
(Use Several Sheets if Necessary)	11/28/00	Unknown

U.S. Patent Documents

Examiner Initial	No.	Patent No.	Date	Patentee	Class	Sub-class	Filing Date

Foreign Patent or Published Foreign Patent Application

Examiner Initial	No.	Document No.	Publication Date	Country or Patent Office	Class	Sub-class	Translation	
							Yes	No

Other Documents

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	O	Parasharya, P .M. and Parikh, A.R. 4-(3H)-Quinazolones part I: 2.Alkyl/arylaminomethyl-3. p-hydroxy/methoxyphenyl.4(3H).quinazolones. **J Inst Chemists** (India) 64: 184-185, 1992.
	P	Parasharya, P .M. et af. 4(3H)-Q~inaZOlones: 2-N-aryValkyl-amino-methyVethyl-3-p-hydroxyphenyll p-anisyl/p-aryaminoacyloxyphenyl/p-N-arylcarbamoylmethoxypheny1-4(3H)-quinazolones. **J Inst Chemists** (India) 64:238-24' .1992.
	Q	Matthews. N. et al. Structure-activity relationships of phenothiazines in inhibiting lymphocyte motility as determined by a novel flow cytometric assay. **Biochem Pharmacol** 50(7):1053-1061.1995.
	R	List of Purchased Compounds 10/00

Examiner	Date Considered

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.